Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

BACKGROUND: The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficac...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Respir Res
Prif Awduron: Liu, Mark C., Chipps, Bradley, Munoz, Xavier, Devouassoux, Gilles, Bergna, Miguel, Smith, Steven G., Price, Robert G., Galkin, Dmitry V., Azmi, Jay, Mouneimne, Dalal, Albers, Frank C., Chapman, Kenneth R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2021
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8111733/
https://ncbi.nlm.nih.gov/pubmed/33971856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01733-9
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg